British company Optibiotix has signed an exclusive manufacturing and supply agreement with Zeon, an Indian healthcare company, for the use of OptiBiotix’s science-based weight management technology, SlimBiome.
A manufacturer of nutraceutical and herbal products, Zeon specialises in developing custom formulations for the food, herbal, and pharmaceutical industries. French food giant Danone and India's Sun Pharmaceutical are among its clients.
Zeon has a DSIR approved R&D lab with a team of professionals who have been actively involved in research on novel molecules and formulations to cater to the latest market demands.
"Zeon’s expertise to manufacture with purity and precision along with Optibiotix’s patented technology is opening new paths for the Indian obesity market," the company said in a statement.
Following the confirmation of the deal, Zeon now has a licence to manufacture and supply SlimBiome across India in return for a 50% profit share.
Optibiotix's SlimBiome received CE mark approval as a medical device in 2018. The technology has been designed to help people consistently manage their weight loss by reducing their food intake while at the same time reducing food cravings.
According to the National Family Health Survey, the number of obese people in India has doubled over the past ten years. Moreover, there were 72 million cases of diabetes in 2017 and reports show that an estimated 122,700 men aged 30 and above die from diabetes in India every year.
This partnership was facilitated by the Department for International Trade, and the Rt. Hon Mark Field, Minister of State for Asia and the Pacific, UK Foreign and Commonwealth Office.